Cardiotoxic drugs: Clinical monitoring and decision making

Heart

Volumn 94, Issue 11, 2008, Pages 1503-1509

  Wu, Audrey H ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; ALKYLATING AGENT; ANTHRACYCLINE DERIVATIVE; ANTIMETABOLITE; ANTINEOPLASTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAPECITABINE; CYCLOPHOSPHAMIDE; CYTARABINE; CYTOKINE; DAUNORUBICIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXORUBICIN; EPIRUBICIN; ERYTHROMYCIN; FLUOROURACIL; FLUOXETINE; GLITAZONE DERIVATIVE; IDARUBICIN; IMATINIB; MITOXANTRONE; MONOCLONAL ANTIBODY; PACLITAXEL; PIOGLITAZONE; PROTEIN TYROSINE KINASE INHIBITOR; RITUXIMAB; SUNITINIB; TRASTUZUMAB; UNINDEXED DRUG;

ALCOHOL ABUSE; ALCOHOL CONSUMPTION; ALCOHOLIC CARDIOMYOPATHY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CARDIOMYOPATHY; CARDIOTOXICITY; CARDIOVASCULAR RISK; CLINICAL FEATURE; CLINICAL TRIAL; CONGESTIVE CARDIOMYOPATHY; DISEASE MARKER; DISEASE SEVERITY; DOSAGE SCHEDULE COMPARISON; DRUG ABUSE; DRUG DOSE REDUCTION; DRUG MECHANISM; DRUG WITHDRAWAL; ECHOCARDIOGRAPHY; FLUID RETENTION; GASTROINTESTINAL STROMAL TUMOR; HEART EJECTION FRACTION; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE BIOPSY; HEART MUSCLE ISCHEMIA; HEMATOLOGIC MALIGNANCY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HORMONAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HYPERTENSION; KIDNEY CARCINOMA; MEDICAL DECISION MAKING; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT MONITORING; PERIPHERAL EDEMA; PRIORITY JOURNAL; QT PROLONGATION; REVIEW; RISK FACTOR; SIDE EFFECT; SYSTOLIC HEART FAILURE; THORAX PAIN; TORSADE DES POINTES;

ANTHRACYCLINES; ANTI-RETROVIRAL AGENTS; ANTIBODIES, MONOCLONAL; CARDIOMYOPATHIES; CARDIOTOXINS; DECISION MAKING; HUMANS; LYMPHATIC IRRADIATION; NEOPLASMS; PYRAZOLES; PYRIMIDINES; SUBSTANCE-RELATED DISORDERS; THIAZOLIDINEDIONES;

EID: 54349120809     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/hrt.2007.133876     Document Type: Review

References (20)

1. Yeh ET, Tong AT, Lenihan DJ, et al. Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circulation 2004;109:3122-31. ▶ Extensive review of the range of cardiovascular complications related to a wide range of anticancer treatments, including clinical management recommendations and practical summary tables.
2. Jones LW, Haykowsky MJ, Swartz JJ, et al. Early breast cancer thetapy and cardiovascular injury. J Am Coll Cardiol 2007;50:1435-41. ▶ Excellent review of cardiovascular complications following breast cancer therapy, with particular emphasis on research data.
3. Lipshultz SE, Alvarez JA, Scully RE. Anthracycline associated cardiotoxicity in survivors of childhood cancer. Heart 2008;94:525-33.
4. Takemura G, Fujiwata H. Doxorubicin-induced cardiomyopathy: ftom the cardiotoxic mechanisms to management. Prog Cardiovasc Dis 2007;49:330-52. ▶ Thorough review of proposed mechanisms and pathophysiology underlying doxorubicin induced cardiomyopathy.
5. Carver JR, Ng A, Meadows AT, et al. Cardiovascular late effects and the ongoing care of adult cancer survivors. Dis Manag 2008;11:1-6.
6. Chu TF, Rupnick MA, Kerkela R, et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 2007;370:2011-9.
7. Hooning MJ, Botma A, Aleman BM, et al. Long-term risk of cardiovascular disease in 10-year survivors of breast cancer J Natl Cancer Inst 2007;99:365-75.
8. Patt DA, Goodwin JS, Kuo YF, et al. Cardiac morbidity of adjuvant radiotherapy for breast cancer. J Clin Oncol 2005;23:7475-82.
9. Nesto RW, Bell D, Bonow RO, et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Circulation 2003;108:2941-8. ▶ Consensus guidelines on data regarding relation between thiazolidinedione treatment and heart failure and practical management recommendations.
10. Dargie HJ, Hildebrandt PR, Riegger GA, et al. A randomized, placebo-controlled trial assessing the effects of rosiglitazone on echocardiographic function and cardiac status in type 2 diabetic patients with New York Heart Association functional class I or II heart failure. J Am Coll Cardiol 2007;49:1696-704.
11. Lago RM, Singh PP, Nesto RW. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet 2007;370:1129-36.
12. Friis-Moller N, Reiss P, Sabin CA, et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007;356:1723-35.
13. Fantoni M, Autore C, Del Borgo C. Drugs and cardiotoxicity in HIV and AIDS. Ann N Y Acad Sci 2001;946:179-99. ▶ Extensive review of cardiac toxicity related to drugs used for HIV treatment, including practical management recommendations.
14. Gupta A, Lawrence AT, Krishnan K, et al. Current concepts in the mechanisms and management of drug-induced QT prolongation and torsade de pointes. Am Heart J 2007;153:891-9. ▶ Thorough and practical review of drug induced QT prolongation, including tables of culprit drugs.
15. Davidoff R, McTiernan A, Constantine G, et al. Echocardiographic examination of women previously treated with fenfluramine: long-term follow-up of a randomized, double-blind, placebo-controlled trial. Arch Intern Med 2001;161:1429-36.
16. Gardin JM, Schumacher D, Constantine G, et al. Valvular abnormalities and cardiovascular status following exposure to dexfenfluramine or phentetmine/fenfluramine. JAMA 2000;283:1703-9.
17. Piano MR. Alcoholic cardiomyopathy: incidence, clinical characteristics, and pathophysiology. Chest 2002;121:1638-50. ▶ Thorough review of proposed mechanisms, clinical features, and management recommendations for alcoholic cardiomyopathy.
18. McCord J, Jneid H, Hollander JE, et al. Management of cocaine-associated chest pain and myocatdial infarction: a scientific statement from the American Heart Association Acute Cardiac Care Committee of the Council on Clinical Cardiology. Circulation 2008;117:1897-907. ▶ Consensus guidelines and expert opinion regarding management of chest pain and acute coronary syndrome related to cocaine toxicity.
19. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33.
20. Juni P, Nartey L, Reichenbach S, et al. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet 2004;364:2021-9.